<DOC>
	<DOCNO>NCT00345865</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide , etoposide , carboplatin , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving colony-stimulating factor , G-CSF , help stem cell move patient 's bone marrow blood collect store peripheral stem cell transplant . Giving chemotherapy , cyclophosphamide , carmustine , etoposide , total-body irradiation prepare patient 's bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . More radiation therapy give transplant kill remain cancer cell . PURPOSE : This phase II trial study well autologous peripheral stem cell transplant work treat patient non-Hodgkin 's lymphoma Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Autologous Peripheral Stem Cell Transplant Treating Patients With Non-Hodgkin 's Lymphoma Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine disease-free survival overall survival patient non-Hodgkin 's Hodgkin 's lymphoma treat autologous peripheral blood stem cell transplantation ( PBSCT ) . - Verify safety efficacy autologous PBSCT patient HIV disease relapse lymphoma . Secondary - Evaluate immune reconstitution HIV-positive patient undergo autologous PBSCT compare immune reconstitution HIV-negative patient . - Predict adequacy peripheral blood stem cell ( PBSC ) harvest prior flow analysis PBSC yield . - Determine time engraftment neutrophils platelet . OUTLINE : - Peripheral blood stem cell ( PBSC ) mobilization filgrastim ( G-CSF ) alone : Patients require disease reduction receive G-CSF subcutaneously ( SC ) daily day 1-8 . Patients undergo PBSC collection leukapheresis day 5-8 . Patients adequately mobilize G-CSF alone proceed chemo-mobilization . - Chemo-mobilization : Patients require disease reduction receive 1 2 chemo-mobilization regimen . - Patients CD20+ non-Hodgkin 's lymphoma ( NHL ) lymphocyte predominant Hodgkin 's lymphoma : Patients receive rituximab intravenously ( IV ) 6-8 hour day 1 , ifosfamide IV 2 hour etoposide IV 30 minute day 2-4 , carboplatin IV 1 hour day 2 . Patients receive G-CSF SC daily begin day 5 continue leukapheresis complete . Patients undergo PBSC collection leukapheresis day 12-15 . - All patient : Patients receive ifosfamide IV 2 hour etoposide IV 30 minute day 1-3 carboplatin IV 1 hour day 1 . Patients receive G-CSF SC daily begin day 4 continue leukapheresis complete . Patients undergo PBSC collection leukapheresis day 12-15 . - Autologous PBSC transplantation ( PBSCT ) ( Patients NHL undergoing irradiation ) : Patients receive cyclophosphamide IV 2 hour day -7 -6 . Patients undergo total body irradiation ( TBI ) twice daily day -4 -1 . Patients undergo autologous PBSCT day 0 . Patients receive G-CSF SC daily begin day 5 continue blood count recover . - Autologous PBSCT ( Patients Hodgkin 's lymphoma NHL undergoing irradiation cyclophosphamide ) : Patients receive camustine IV 2 hour day -6 , etoposide IV 2 hour twice daily day -5 -2 , melphalan 1 hour day -1 . Patients undergo autologous PBSCT day 0 . Patients receive G-CSF SC daily begin day 5 continue blood count recover . - Autologous PBSC transplantation ( PBSCT ) ( Patients HL undergoing irradiation ) : Patients receive cyclophosphamide IV 2 hour day -6 -3 , camustine IV 2 hour day -6 , etoposide IV 4 hour twice daily day -6 -4 . Patients undergo autologous PBSCT day 0 . Patients receive G-CSF SC daily begin day 5 continue blood count recover . - Post-transplant irradiation : Patients undergo post-transplant irradiation begin day 28 . Persisting nodal mass ≥ 2 cm treat additional localized external beam irradiation . - Post-transplant Rituximab therapy : patient CD20+ NHL may undergo Rituximab maintenance start day +45 +90 repeat day +180 ± 14 day . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 300 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Karnofsky performance status : &gt; 80 % ( &gt; 60 % poor performance status relate lymphoma ) No evidence serious organ dysfunction attributable tumor Central nervous system : Patients history CNS involvement lymphoma relapse primary lymphoma eligible . Infection : Patients serious uncontrolled infection time transplant exclude . Hepatitis B : Patients carrier Hepatitis B include study . These patient eligible receive rituximab component chemotherapy mobilization . HIV disease . Patients HIV disease eligible study provide : Patients see infectious disease ( ID ) /HIV clinic prior enrollment study purpose determine eligibility local coordination HIV care peritransplant period . Must maximally active antiHIV regimen CD4+ ≥ 50/μL HIV RNA viral load ≤ 100,000 copy per mL sample 4 week apart . The recent level must within one month enrollment . NonHodgkin 's lymphoma ( NHL ) . Patients chemosensitive histologically confirm NHL . Precursor Bcell Precursor Tcell NHL Lymphoblastic lymphoma All patient eligible second great complete remission ( CR ) first subsequent partial remission ( PR ) Mature Bcell Lymphomas : Small lymphocytic lymphoma ( SLL ) Chronic Lymphocytic Leukemia ( CLL ) Follicular Lymphoma Diffuse Large Bcell Lymphoma Mantle Cell Lymphoma Burkitt's/Burkitt 's like Mature Tcell lymphoma Hodgkin 's lymphoma ( HL ) patient histologically proven HL eligible transplantation fail prior therapy . Patients eligible high priority transplant protocol Women pregnant breast feeding Patients chemotherapy resistant disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>HIV-associated lymphoma</keyword>
</DOC>